Results 101 to 110 of about 14,687 (252)

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Prediction of Pharmacokinetic Drug–Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling

Drug Design, Development and Therapy
Fengjiao Bu,1,2,* Yong-Soon Cho,3,4,* Qingfeng He,1 Xiaowen Wang,1 Saurav Howlader,3,4 Dong-Hyun Kim,3,4 Mingshe Zhu,5 Jae Gook Shin,3,4 Xiaoqiang Xiang1,6 1Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan ...
Bu F, Cho YS, He Q, Wang X, Howlader S, Kim DH, Zhu M, Shin JG, Xiang X   +8 more
doaj  

EURL ECVAM Workshop on New Generation of Physiologically-Based Kinetic Models in Risk Assessment [PDF]

, 2017
The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) Strategy Document on Toxicokinetics (TK) outlines strategies to enable prediction of systemic toxicity by applying new approach methodologies (NAM).
Bessems, J, Desalegn, A, Dorne, JL, Gosling, JP, Heringa, MB, Joossens, E, Klaric, M, Kramer, N, Loizou, G, Louisse, J, Lumen, A, Madden, JC, Paini, A, Patterson, EA, Proenca, S, Punt, A, Setzer, RW, Suciu, N, Tan, YM, Troutman, J, Worth, A, Yoon, M   +21 more
core   +2 more sources

Evaluating Thiram‐Induced Embryotoxicity Using Integrated In Silico, In Vitro, and Transcriptomic Approaches

Environmental Toxicology, EarlyView.
ABSTRACT Long‐term exposure to low‐dose food contact materials (FCMs) has raised concerns regarding developmental toxicity. In the present study, we prioritized FCMs with potential developmental toxicity using a weight‐of‐evidence computational model, which predicted 127 chemicals to be of high concern.
Chia‐Chi Ho, Chun‐Wei Tung, B. Linju Yen, Chen‐Yi Weng, Ju‐Hsin Hsu, Ming‐Hsien Tsai, Salim Arrokhman, Pinpin Lin   +7 more
wiley   +1 more source

Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1584-1596, June 2026.
Pediatric populations differ from adults in drug elimination capacity. While current scaling methods account for enzyme and transporter maturation, they overlook comorbidities, such as biliary atresia (BA), a liver disease appearing within the first 2–8 weeks of life that can progress to cirrhosis.
Zubida M. Al‐Majdoub, Martyn Howard, Brahim Achour, Jill Barber, Naved Alizai, Amin Rostami‐Hodjegan   +5 more
wiley   +1 more source

Integration of Machine Learning With PBPK and QSAR Modeling Approaches to Facilitate Drug Discovery and Development

CPT: Pharmacometrics & Systems Pharmacology
This review examines the application of machine learning (ML) in physiologically based pharmacokinetic (PBPK) modeling through improved prediction of input parameters, particularly via quantitative structure–activity relationship (QSAR) models, for ...
Xinyue Chen, Zhoumeng Lin
doaj   +1 more source

From PK/PD to QSP: Understanding the Dynamic Effect of Cholesterol-Lowering Drugs on Atherosclerosis Progression and Stratified Medicine [PDF]

, 2016
Current computational and mathematical tools are demonstrating the high value of using systems modeling approaches (e.g. Quantitative Systems Pharmacology) to understand the effect of a given compound on the biological and physiological mechanisms ...
Diaz-Zuccarini, V, Pichardo-Almarza, C
core  

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Evaluation of Luteolin Nanosuspensions on Pharmacokinetics of Atorvastatin: Drug-Drug Interactions Using Rat Models

International Journal of Nanomedicine
You Liang,* Bo Sun,* Min Yang, Xiaona Meng, Meng Wang, Lijuan Yang, Bandar AI-Hamyari, Yuqian Zhang, Yutong Shen, Shengnan Meng Department of Pharmaceutics, School of Pharmacy, China Medical University, Shenyang, 110122, People’s Republic of ...
Liang Y, Sun B, Yang M, Meng X, Wang M, Yang L, AI-Hamyari B, Zhang Y, Shen Y, Meng S   +9 more
doaj  

Use of Physiologically Based Pharmacokinetic (PBPK) Models in Marine Mammal Toxicology [PDF]

, 2012
peer reviewedPhysiologically based pharmacokinetic (PBPK) models are mathematical models that are largely based upon the physiological characteristics of the species and the biochemical properties of the chemical of interest. They quantitatively describe
Blust, Ronny, Covaci, Adrian, Das, Krishna, Weijs, Liesbeth, Yang, Raymond S.H.   +4 more
core